ClinicalTrials.gg
WithdrawnNCT01868685Updated Jan 7, 2015

Study of Muscle Effects of BYM338 in Mechanically Ventilated Patients

A Phase 2 interventional study of BYM338 and Placebo in Mechanical Ventilation, sponsored by Novartis Pharmaceuticals. Withdrawn. Per ClinicalTrials.gov, last updated 2015-01-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of BYM338 on muscle mass and function in Group III failure to wean patients, as compared to placebo controls.

02

Conditions studied

  • Mechanical Ventilation

Keywords

  • Muscle, anabolism, cachexia, respiratory failure, diaphragm
03

In context

Cachexia

331 studies on the registry are indexed under Cachexia; 74 are open to participants now.

Browse Cachexia studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults on mechanical ventilation for at least 7 days with a tracheostomy in place for >24 hours.
  • Expected to survive at least 14 days.
  • Receiving adequate nutritional support, defined as at least 20 kcal/kg and 0.6 g/kg protein per day (unless lower protein intake required by clinical status).

Exclusion criteria

Exclusion Criteria:

  • Patients deemed to be terminal wean patients.
  • Patients who have progressive neuromuscular degenerative disorders.
  • Patients who are comatose.
  • Evidence of unstable medical status.
05

Study design

Phase
Phase 2
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    BYM338

    Drug: BYM338

Interventions

  • DrugBYM338

    BYM338

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change in thigh muscle thickness

    Time frame: After 14 days

Secondary outcomes

  1. Number of patients with adverse events as a measure of safety and tolerability

    Time frame: After 12 weeks

  2. Sparse sampling of BYM338 serum levels to assess pharmacokinetic profile in mechanically ventilated patients

    Time frame: After 12 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2013
First posted
Jun 4, 2013
Start
Apr 2014
Primary completionEst.
Jan 2015
CompletionEst.
Jan 2015
Last update
Jan 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01868685
Responsible party
Sponsor
First posted
Jun 4, 2013
Start date
Apr 2014
Primary completion
Jan 2015 (estimated)
Completion
Jan 2015 (estimated)
Last update
Jan 7, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimagrumab

Start the discussion